Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in place—and provide our editorial team with your valued feedback: www.laserfocusworld.com/membership/signup/member?redirectTo=

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Subscribe

Can you subscribe to receive our print issue for free? Yes, you sure can! Right here: https://endeavor.dragonforms.com/loading.do?omedasite=lfw_NEW

Laser Focus World newsletter subscription is free to qualified professionals. Subscribe here.

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics. Watch here

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community. Listen here

Meet the Laser Focus World Team

Editorial

Contact Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Biogen Earnings: What To Look For From BIIB

BIIB Cover Image

Biotech company Biogen (NASDAQ: BIIB) will be reporting results this Thursday morning. Here’s what you need to know.

Biogen beat analysts’ revenue expectations by 8.6% last quarter, reporting revenues of $2.43 billion, up 6.1% year on year. It was a satisfactory quarter for the company, with a decent beat of analysts’ EPS estimates but a slight miss of analysts’ full-year EPS guidance estimates.

Is Biogen a buy or sell going into earnings? Read our full analysis here, it’s free.

This quarter, analysts are expecting Biogen’s revenue to decline 5.6% year on year to $2.33 billion, a deceleration from its flat revenue in the same quarter last year. Adjusted earnings are expected to come in at $3.88 per share.

Biogen Total Revenue

Heading into earnings, analysts covering the company have grown increasingly bearish with revenue estimates seeing 8 downward revisions over the last 30 days (we track 24 analysts). Biogen has missed Wall Street’s revenue estimates twice over the last two years.

Looking at Biogen’s peers in the biotechnology segment, only Incyte has reported results so far. It beat analysts’ revenue estimates by 5.5%, delivering year-on-year sales growth of 16.5%.

Read our full analysis of Incyte’s earnings results here.

Investors in the biotechnology segment have had fairly steady hands going into earnings, with share prices down 1.8% on average over the last month. Biogen is up 3.4% during the same time and is heading into earnings with an average analyst price target of $168.85 (compared to the current share price of $129.80).

Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.